UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...

Gothenburg, February 27, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next-generation cancer treatments based on its proprietary iTANK platform, tod ...

Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global ...

As interest in CAR T cells and immune-based oncology therapies increases, efficient phenotyping of cell therapy products ...

The field of bovine immunology has made significant strides in understanding the biology and function of T cells, which are crucial players in shaping ...

Cullinan Therapeutics has a robust T-cell engager pipeline, savvy management, and a strong cash position. Read more on what investors should know about the company.

Company announces manufacturing readiness and financing extension ahead of first-in-human clinical studyLondon, United Kingdom, March 5, 2026, ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across eight U.S. sites.

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided ...

A 56-year-old man with liver failure has become the first living person to be surgically connected to a genetically modified ...

The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As described in the patent application, STAR-LLD's ...

So far, in a Phase I trial, incidents of CRS have been low grade on VIR-5500, and 14 of 17 evaluable patients saw more than a 50 percent decrease in PSA levels.